Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of MenABCWY vaccine in healthy adolescents
2015-000979-27Phase 2
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in meningococcal disease comparing MenABCWY vaccine with MenACWY vaccine control (2 arms). Primary endpoint: Percentage of subjects without bactericidal serum activity at 1:4 dilution using enc-hSBA against each endemic US serogroup B strain.
02
Drugs
Meningococcal ABCWYmeningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2015-000979-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000979-27.